USA Archives

News and Trends 9 Sep 2022

Beyond Biotech podcast 13: BioInnovation Institute, IASP

This week’s guests on the podcast are Bobby Soni, chief business officer at the BioInnovation Institute; and Harriet Edwards, International Association of Science Parks (IASP) media and community manager. We also have our weekly chat with global commercial real estate services company JLL, and this week it is with Travis McCready. IASP to host World […]

September 9, 2022

News and Trends 8 Sep 2022

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen manufacturing capabilities for single-use assemblies – a key technology for the production of Covid-19 vaccines and other life-saving therapies. The investment was made by MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA. It is the largest ever […]

September 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

Integral Molecular joins FDA’s ISTAND program

Integral Molecular has been accepted into the U.S. Food & Drug Administration (FDA)’s ISTAND (Innovative Science and Technology Approaches for New Drugs) pilot program. The program supports, and was created to expand, the drug development tool types listed in the 21st Century Cures legislation. A major goal of the pilot program is to qualify these […]

September 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Sep 2022

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis BioTherapeutics will acquire the outstanding shares of Ducentis for an upfront cash payment of approximately $16 million and Arcutis stock valued at approximately $14 million, […]

September 8, 2022 - 4 minutesmins - By Jim Cornall

In Depth 7 Sep 2022

The biggest private biotech investments in August 2022

The healthcare-focused companies Orna Therapeutics, F2G and Sironax bagged the biggest biotech investments in August 2022, with mRNA vaccines, genomics and fermentation technology attracting big funding rounds. As many took a well-deserved vacation in the month of August 2022, the world of biotech remained busy with fundraising. Sit back and browse our lists of the […]

September 7, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Sep 2022

Lesaffre acquires genome editing company Recombia Biosciences

Lesaffre has acquired Recombia Biosciences, a biotech company based in the San Francisco Bay Area founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

The first patient has been dosed in a phase 2 trial looking at a drug to treat peripheral T cell lymphomas – a heterogenous group of generally aggressive neoplasms. Yingli Pharma made the announcement on Saturday (September 3) that patients were being dosed with linperlisib – a potent inhibitor of the delta isoform of PI3 […]

September 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

A drug to treat soft tissue sarcoma has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Clinical stage oncology drug company Avacta Group plc has produced a form of the generic chemotherapy, doxorubicin AVA6000. About Avacta’s drug The drug has been modified using the company’s pre|CISION technology and Affirmer […]

September 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Sep 2022

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug

More than half of patients treated for psoriasis with an intravenous injection showed no visible pustules just one week after receiving treatment. Boehringer Ingelheim announced today (September 2) that the U.S. Food and Drug Administration (FDA) has approved the first treatment option, SPEVIGO, for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, […]

September 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Sep 2022

Beyond Biotech podcast 12: Gate Neurosciences, Oncolyze, 3Brain

This week’s podcast guests are Mike McCully, CEO of Gate Neurosciences; Steven Evans, CEO and co-founder of Oncolyze; and Philipp Markolin, scientific marketing specialist at 3Brain. We also have our weekly chat with global commercial real estate services company JLL, and this week it’s a chat with Amber Schiada, head of life sciences research in […]

September 2, 2022

News and Trends 2 Sep 2022

Manus Bio receives additional funding to fight malaria with biotech

U.S. biomanufacturer Manus Bio has received a fourth award from the Bill & Melinda Gates Foundation to develop a scalable production route for the potential antimalarial drug, artemisinin. The $2 million award will enable Manus Bio to begin scaling up the biological process it has developed towards the chemical intermediate, dihydroartemisinic acid. Economical and scalable […]

September 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 1 Sep 2022

Study of injection to treat schizophrenia to begin after $3M payment received

A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million payment was received by MedinCell. Teva Pharmaceuticals made the decision to start the trial for mdc-TJK this week (August 29). Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia can produce a […]

September 1, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Beyond Biotech podcast 13: BioInnovation Institute, IASP

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

Integral Molecular joins FDA’s ISTAND program

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

The biggest private biotech investments in August 2022

Lesaffre acquires genome editing company Recombia Biosciences

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug

Beyond Biotech podcast 12: Gate Neurosciences, Oncolyze, 3Brain

Manus Bio receives additional funding to fight malaria with biotech

Study of injection to treat schizophrenia to begin after $3M payment received

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!